Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





Reported Tuberculosis in the United States, 2020					minus icon
                Table of Contents
			National DataState & Local DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBGenotype ClustersEstimates of Recent Transmission					Related Pages
					Return to Main Menu
DemographicsOn This Page
			HighlightsOrigin of BirthRace/EthnicityAgeSexData TablesHighlightsDemographic characteristics analysis includes
Origin of Birth
Race/Ethnicity
Age
SexDemographic characteristics of people diagnosed with TB disease remain similar to previous years.Origin of BirthBecause of the substantially greater risk of exposure to TB bacteria outside of the United States, origin of birth is the most prominent risk factor for TB in the United States.
TB Cases and Incidence Rates by Origin of Birth, United States, 1993–2020resize iconView LargerCloseTB Cases and Incidence Rates by Origin of Birth, United States, 1993–2020download iconDownload Image[PNG]
Consistent with previous years, the majority of reported TB cases occurred among non-U.S.–born persons (71.5%) (TB by Origin of Birth: 1993–2020).
Between 1993 and 2020
Cases of TB disease have declined by 88.4% among U.S.-born persons and by 30.8% among non-U.S.–born persons.Incidence rates (per 100,000 persons) of TB disease
have declined by 90.3% among U.S.-born persons and by 65.7% among non-U.S.–born persons.Among non-U.S.–born persons with TB disease, the most common countries of birth continue to include
Top Countries of Birth Among Non-U.S.–born Persons with TB, United States, 2020 (N=5,127)resize iconView LargerCloseTop Countries of Birth Among Non-U.S.–born Persons with TB, United States, 2020 (N=5,127)download iconDownload Image[PNG]
Mexico; 18.0%,
the Philippines; 12.5%,
India; 10.4%,
Vietnam; 8.2%, and
China; 5.1%.*Source: TB Among Non-U.S.–Born Persons by the Top 30 Countries of Birth: 2016–2020*
These countries of birth also represent substantial proportions of the non-U.S.–born population living in the United States.
Groups with relatively small populations in the United States can have high incidence rates despite constituting a relatively small proportion of the total number of TB cases reported because incidence rates accounts for the size of the underlying population.
Top 10 TB Incidence Rates,* by Country of Birth,† United States, 2016–2020resize iconView LargerCloseTop 10 TB Incidence Rates,* by Country of Birth,† United States, 2016–2020download iconDownload Image[PNG]
Among non-U.S.–born persons, the countries of birth with the highest incidence rates (per 100,000 persons) of TB disease were
the Republic of the Marshall Islands; 164.2,
the Republic of the Congo; 120.8,
Somalia; 81.2, and
Myanmar; 73.5.*Source: TB Rates by the Top 10 Countries of Birth in the United States: 2016–2020*Race/EthnicityPercentage of TB Cases by Race/Ethnicity,* United States, 2020 (N=7,174)†resize iconView LargerClosePercentage of TB Cases by Race/Ethnicity,* United States, 2020 (N=7,174)†download iconDownload Image[PNG]
Anyone can get TB disease, but some groups are at increased risk for TB.
In 2020, the majority of persons with TB disease in the United States identified as
Non-Hispanic Asian persons (35.8%),
Hispanic or Latino persons (29.7%),
Non-Hispanic Black or African American persons (19.6%), or
Non-Hispanic White persons (11.0%).*Source: TB by Race/Ethnicity: 1993–2020*
Percentage of TB Cases by Race/Ethnicity,* United States, 2020 (N=7,174)†resize iconView LargerClosePercentage of TB Cases by Race/Ethnicity,* United States, 2020 (N=7,174)†download iconDownload Image[PNG]
The incidence rate (per 100,000 persons) remained highest among non-Hispanic Native Hawaiian or Other Pacific Islander persons in 2020 (18.7 per 100,000 persons), and this is the only race/ethnicity group in which the rate did not decrease compared with 2019 (17.5 per 100,000 persons).
As in past years, the distribution of persons with TB disease and the incidence rates by race/ethnicity differ markedly in 2020 by origin of birth (TB by Race/Ethnicity Among U.S.–Born Persons: 1993–2020, TB by Race/Ethnicity Among Non-U.S.–Born Persons: 1993–2020, and TB by Race/Ethnicity and Origin of Birth: 1993–2020).AgeTB Incidence Rates by Age Group, United States, 1993–2020resize iconView LargerCloseTB Incidence Rates by Age Group, United States, 1993–2020download iconDownload Image[PNG]
The age distribution among persons with TB disease has remained relatively steady over time; similar to past years, the majority (95.5%) of persons with TB disease in 2020 occurred in persons 15 years of age or older (TB by Age Group: 1993–2020).
Children ages 5–14 years had the lowest TB incidence rate (0.4 cases per 100,000 persons) and were the only age group whose incidence rate did not decrease in 2020.
Adults 65 years of age or older had the highest TB incidence rate in 2020 (3.4 per 100,000 persons) and experienced the largest percentage decrease (24.3%) compared with 2019 (4.5 per 100,000).SexPercentage of TB Cases by Sex and Age Group, United States, 2020resize iconView LargerClosePercentage of TB Cases by Sex and Age Group, United States, 2020download iconDownload Image[PNG]
Males accounted for 60.6% of TB cases in the United States in 2020 and had a higher incidence rate (2.7 per 100,000 persons) compared with females (1.7 per 100,000 persons).
Among persons 15 years of age and older, males accounted for more than half (61.2%) of cases; however, among children 0–14 years of age, less than half (46.7%) of TB cases occurred in male persons (TB by Race/Ethnicity, Sex, and Age: 2020).
This might indicate that factors associated with increased risk for TB disease (such as homelessness, incarceration, and substance use) disproportionately affect adult men or that migration patterns to the United States differ by sex and age.
Learn more in the Executive Commentary.Data Tables
Open All Close AllDemographicsCharacteristics of TB Cases in GENType Clusters by Alert Levels: 2018–2020
Characteristics of TB Estimated to be Attributed to Recent Transmission: 2019–2020Origin of BirthTB by Race/Ethnicity Among Non-U.S.–Born Persons: 1993–2020
TB by Race/Ethnicity and Origin of Birth: 1993–2020
TB by Origin of Birth: 1993–2020
TB Among Non-U.S.–Born Persons by the Top 30 Countries of Birth: 2016–2020
TB Rates by the Top 10 Countries of Birth in the United States: 2016–2020
TB Among Non-U.S.–Born Persons by Years in the United States: 1993–2020
TB by Resistance to Isoniazid (INH): 1993–2020
TB by Multidrug Resistance (MDR): 1993–2020
*Mycobacterium bovis* by Origin of Birth: 2004–2020
TB Among Non-U.S.–Born Persons, by Top Countries of Birth and Years in the United States: 2020
TB Among U.S.-Born Persons, by Race/Ethnicity, Sex, and Age: 2020
TB Among Non-U.S.–Born Persons, by Race/Ethnicity, Sex, and Age: 2020
TB Risk Factors, by Origin of Birth and Race/Ethnicity: 2020
TB by Origin of Birth: United States and the District of Columbia, 2020
TB by Origin of Birth: Metropolitan Statistical Areas with ≥500,000 Population, 2020Race/EthnicityTB by Race/Ethnicity: 1993–2020
TB by Race/Ethnicity Among U.S.-Born Persons: 1993–2020
TB Among U.S.-Born Persons, by Race/Ethnicity, Sex, and Age: 2020
TB by Hispanic Ethnicity and Race: Reporting Areas, 2020
TB by Race/Ethnicity: Metropolitan Statistical Areas with ≥500,000 Population, 2020AgeTB by Age Group: 1993–2020
TB by Age Group Among U.S.-Born Persons: 1993–2020
TB by Age Group Among Non-U.S.–Born Persons: 1993–2020
TB by Birth Cohort: 1993–2020
TB by Age Group: Reporting Areas, 2020
TB by Age Group: Metropolitan Statistical Areas with ≥500,000 Population, 2020SexTB by Race/Ethnicity, Sex, and Age: 2020
TB Among U.S.-Born Persons, by Race/Ethnicity, Sex, and Age: 2020
TB Among Non-U.S.–Born Persons, by Race/Ethnicity, Sex, and Age: 2020Top of Page
					PrevRisk Factors
			NextTB Treatment and ...
							
					
						Page last reviewed:  October 25, 2021					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue